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1. Introduction 
Cancer is a multistage disease involving a series of events and generally occurs over an 
extended period. During this period, accumulation of genetic and epigenetic alterations 
leads to the progressive transformation of a normal cell into a malignant cell. Cancer cells 
acquire several abilities that most healthy cells do not possess: they become resistant to 
growth inhibition, proliferate without dependence on growth factors, replicate without 
limit, evade apoptosis, and invade, metastasize and support angiogenesis [1]. Unlike heart 
disease, death rates for cancer remained approximately the same in the United States from 
1975 through 2002. Indeed, it is predicted that by 2020 approximately 15 million new cancer 
cases will be diagnosed worldwide and 12 million cancer patients will die [2]. 
Cancer is a disease characterized by uncontrolled growth and division of genetically altered 
cells and its emergence requires several elements, including self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative 
potential, tissue invasion and metastasis, and sustained angiogenesis [1, 3]. Cancer is 
thought to evolve along a multi-step process. Cancer cells are the descendants of a normal 
cell in which some kind of internal or external stress causes a change in its genetic code. This 
event is said to initiate the cell to a precancerous state. In a second stage, this precancerous 
cell divides in response to a promoting agent to produce daughter cells, and these daughter 
cells divide to produce more daughter cells, and so on. The genetic instabilities passed down 
through the generations finally result in one cell that no longer requires the promoting agent 
to stimulate its proliferation. A cancer cell is thus born with the ability to make proteins such 
as growth factors that stimulate proliferation. Finally in the third stage of carcinogenesis, 
progression, this cancer cell divides to produce daughter cells, which also divide, and soon 
there is a population of cancer cells with the ability to invade and metastasize [4]. 
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It is now clear that cancer phenotypes result from the dysregulation of more than 500 genes 
at multiple steps in cell signaling pathways. This indicates that inhibition of a single gene 
product or cell signaling pathway is unlikely to prevent or treat cancer. However, most 
current anticancer therapies are based on the modulation of a single target [5, 6]. 
One of the most important findings to have emerged during the past three decades is that 
cancer is a largely preventable disease. Thus, people need to be educated about the risk 
factors for cancer and those that prevent the disease. As many as 90% of all cancers have 
been shown to be due to environmental/acquired factors such as tobacco, diet, radiation and 
infectious organisms, etc., and only the remaining 5–10% of cases are caused by internal 
factors such as inherited mutations, hormones, and immune conditions [7]. 
The ineffective, unsafe, and expensive monotargeted therapies have led to a lack of faith in 
these approaches. Therefore, the current paradigm for cancer treatment is either to combine 
several monotargeted drugs or to design drugs that modulate multiple targets. As a result, 
pharmaceutical companies have been increasingly interested in developing multitargeted 
therapies. Many plant-derived dietary agents, called nutraceuticals, have multitargeting 
properties. In addition, these products are less expensive, safer, and more readily available 
than are synthetic agents [5]. 
Prevention is better than cure and this is very true in case of cancer. Chemoprevention was 
defined as the administration of agents to prevent induction, to inhibit or to delay the 
progression of cancer [8], or as the inhibition or reversal of carcinogenesis at a premalignant 
stage [9]. Chemoprevention involves the use of synthetic or natural compounds to inhibit, 
slow, or reverse carcinogenesis. It is based on the hypothesis that the disruption of biological 
events involved in carcinogenesis will inhibit this process and can be applied to any stage of 
carcinogenesis. Chemoprevention utilizes appropriate pharmacological agents [10,11] or 
dietary agents, consumed in diverse forms like macronutrients, micronutrients, or 
nonnutritive phytochemicals [12–14]. It is estimated that from 10 to 80 percent of cancer 
patients use some form of natural compounds as a part of complementary medicine as part 
of their overall therapy without any real guidance. This explains the growing interest in 
using the natural compounds properly in the treatment of cancer. 
Phytochemicals are one wide class of nutraceuticals found in plants, which are extensively 
researched by scientists for their health-promoting potential. Honey has a wide range of 
phytochemicals including polyphenols which act as antioxidants. Polyphenols and phenolic 
acids found in the honey vary according to the geographical and climatic conditions. Some 
of them were reported as a specific marker for the botanical origin of the honey. 
Considerable differences in both composition and content of phenolic compounds have 
been found in different unifloral honeys [15]. Terpenes, benzyl alcohol, 3, 5-dimethoxy-4-
hydroxybenzoic acid (syringic acid), methyl 3, 5-dimethoxy-4-hydroxybenzoate (methyl 
syringate), 3, 4, 5-trimethoxybenzoic acid, 2-hydroxy-3- phenylpropionic acid, 2-
hydroxybenzoic acid and 1, 4- dihydroxybenzene are some of the phytochemicals a ascribed 
for the antimicrobial activity of honey [16]. Among these phytochemicals, polyphenols were 
reported to have antiproliferative potential.  
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2. Active compounds in propolis 
Polyphenolic compounds are widely distributed in the plant kingdom and display a variety 
of biological activities, including chemoprevention and tumor growth inhibition. Propolis 
and honey have been known to mankind from the remotest of ancient times and have been 
widely used by many cultures for different purposes. Propolis is a complex resinous 
mixture gathered from plants and used by honeybees in their hives as a general-purpose 
sealer and antibiotic. It is made up of a variety of polyphenolic compounds. Some of the 
isolated compounds have shown anti-inflammatory activity, carcinostatic, anti-carcinogenic 
activity and induction of apoptosis. Caffeic acid (CA) and caffeic acid phenethyl ester 
(CAPE) are members of the polyphenolic compounds and present in high concentrations in 
medicinal plants and propolis. CAPE showed a wide variety of biological activities at non-
toxic concentrations. It has shown antibacterial, anti-inflammatory, antioxidant, antitumor 
and anti-proliferative activities [17]. 
CAPE [2-propenoic acid, 3-(3,4-dihydroxy phenyl)-,2-phenethyl ester] (Fig.1) is an active 
component of propolis with a variety of biological activities. CAPE has been used in folk 
medicine as a potent antibacterial, anti-inflammatory, antioxidant, antitumor and 
antiproliferative with a wide variety of biological and pharmacological activities at non-
toxic concentrations in a mammal's organs [18]. 
 
Figure 1. Structure of caffeic acid phenethyl ester (CAPE) 
CAPE is chemopreventive against intestinal, colon and skin cancer, and also has been 
shown to decreases the formation of preneoplastic hepatic lesions when is administrated in 
a rat model of liver carcinogenesis [19-21], but the mechanism of these properties is not 
completely understood. Recently, CAPE, in a concentration dependent fashion, was shown 
to inhibit MCF-7 (hormone receptor positive, HR+) and MDA-MB-231 (a model of triple 
negative BC (TNBC)) tumor growth, either in vitro or in vivo without much effect on normal 
mammary cells [22]. At the same time, CAPE was found to cause pronounced changes in 
bCSC characteristics manifested by inhibition of self renewal, progenitor formation, 
clonal growth in soft agar, and concurrent significant decrease in CD44 content, all signs of 
decreased malignancy potential [23]. Besides CAPE, other caffeic acid esters in propolis may 
have biological effects. 
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Here we will focus on CAPE and its biological effects against cancer in vitro and in vivo. 
Specifically, we will discuss how CAPE can modulate inflammatory pathways and thus 
affect the survival, proliferation, invasion, angiogenesis, and metastasis of the tumor. 
2.1. Regulation of inflammatory pathways by CAPE 
Inflammation is a localized reaction of tissue to infection, irritation, or other injury. 
Inflammation is a necessary response to clear bacterial and viral infections, repair tissue 
insults, and suppress tumor initiation/progression. However, when inflammation persists or 
control mechanisms are dysregulated, diseases such as cancer can develop. Interestingly, 
inflammation functions at all stages of tumor development: initiation, promotion and 
progression including metastasis. During the initiation phase, inflammation induces the 
release of a variety of cytokines and chemokines that promote the activation of 
inflammatory cells and associated factors. This causes further oxidative damage, DNA 
mutations, and other changes in the tissue microenvironment, making it more conducive to 
cell transformation, increased survival, and proliferation [24]. At the molecular level, 
inflammation, transformation, survival and proliferation are regulated by the 
proinflammatory transcription factor Nuclear Factor-κB (NF-κB), a family of ubiquitously 
expressed transcription factors. NF-κB regulates the expression of genes involved in the 
transformation, survival, proliferation, invasion, angiogenesis and metastasis of tumor cells 
[25]. 
TNF-α is also one of the prime signals that induces apoptosis in many different types of 
cells. Whereas acute activation of NF-κB may be therapeutic, chronic activation may lead to 
the development of chronic inflammation, cancer and other chronic diseases. There is a 
strong association between chronic inflammatory conditions and cancer specific to the 
organ. Epidemiological evidence points to a connection between inflammation and a 
predisposition for the development of cancer, i.e., long-term inflammation leads to the 
development of dysplasia. Various factors are known to induce chronic inflammatory 
responses that further cause cancer. These include bacterial, viral, and parasitic infections 
(e.g., Helicobacter pylori, Epstein-Barr virus, human immunodeficiency virus, flukes, 
schistosomes) and chemical irritants (i.e., tumor promoters). Active NF-κB has now been 
identified in tissues of most cancer patients, including those with leukemia and lymphoma 
and cancers of the prostate, breast, oral cavity, liver, pancreas, colon and ovary [26]. 
In the resting stage, NF-κB resides in the cytoplasm as a heterotrimer consisting of p50, p65, 
and the inhibitory subunit IκBα. On activation, the IκBα protein undergoes 
phosphorylation, ubiquitination, and degradation. p50 and p65 are then released, are 
translocated to the nucleus, bind specific DNA sequences present in the promoters of 
various genes, and initiate their transcription. A number of proteins are involved in the NF-
κB signaling pathway. Because of the relevance of the NF-κB signaling pathway in cancer, 
this pathway has been proven to be an attractive target for therapeutic development. 
Active NF-κB complexes can contribute to tumorigenesis by regulating genes that promote 
the growth and survival of cancer cells, during the cell cycle. NF-κB has ability to regulate 
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the G1-phase expression of key proto-oncogenes is subject to regulation by the 
integrated activity of IkappaB kinase (IKK)alpha, IKKbeta, Akt and Chk1. The coordinated 
binding of NF-κB subunits to the Cyclin D1, c-Myc and Skp2 promoters is dynamic with 
distinct changes in promoter occupancy and RelA(p65) phosphorylation occurring through 
G1, S and G2 phases, concomitant with a switch from coactivator to corepressor recruitment. 
Akt activity is required for IKK-dependent phosphorylation of NF-κB subunits in G1 and G2 
phases, where Chk1 is inactive. However, in S-phase, Akt is inactivated, while Chk1 
phosphorylates RelA and associates with IKKalpha, inhibiting the processing of the p100 
(NF-κB2) subunit, which also plays a critical role in the regulation of these genes. This 
reveals a complex regulatory network integrating NF- κB with the DNA-replication 
checkpoint and the expression of critical regulators of cell proliferation [27]. Thus, its 
inhibition could be a novel approach to breaking the vicious cycle of tumor cell proliferation 
[28-30] More than 700 inhibitors of the NF-κB activation pathway have been reported, 
including antioxidants, peptides, small RNA/DNA, microbial and viral proteins, small 
molecules, and engineered dominant-negative or constitutively active polypeptides [31,32].  
Caffeic acid phenethyl ester has been shown to suppress NF-κB activation by suppressing 
the binding of the p50–p65 complex directly to DNA [33-35]. The molecular basis of CAPE 
action was elucidated by Natarajan et al. [36]. Since NF-κB has a role in these activities, they 
examined the effect of CAPE on this transcription factor in an exhaustive manner. They 
preincubated the U-937 cells with CAPE at various concentrations for 2 hours before 
treating with TNF (0.1 nM) for 15 minutes. CAPE inhibited the TNF-dependent activation of 
NF-κB in a dose-dependent manner with maximum effect occurring at 25 μg/mL. NF- κB 
activation induced by the phorbol ester, phorbol-12- myristate 13-acetate (PMA), ceramide, 
okadaic acid and hydrogen peroxide was also inhibited by CAPE. It prevented the 
translocation of the p65 subunit of NF-κB to the nucleus without affecting the TNF-induced 
IκBα degradation. It did not show any inhibitory effects on the other transcription factors 
like AP-1, TFIID and oct-1. With these findings they concluded that CAPE is a potent and a 
specific inhibitor of NF-κB activation and this may provide the molecular basis for its 
multiple immunomodulatory and antiinflammatory activities of CAPE. 
Abdel-Latif et al.[37] have demonstrated for the first time that CAPE is a major component 
of propolis, modulates H. pylori-induced NF-κB, AP-1 DNA binding activity and COX-2 
expression in gastric epithelial cells. In addition, CAPE reduced TNF-α and IL-8 levels and 
suppressed the proliferative response of AGS cells to H. pylori. They found also that 
pretreatment of gastric epithelial cells with CAPE upregulated IkB-a levels and prevented 
nuclear translocation of NF-κB/ p65 in H. pylori-treated AGS cells. NF-κB is present in the 
cytosol in an inactive state bound to the inhibitory IkB protein. H. pylori infection of gastric 
epithelial cells results in phosphorylation and degradation of the IkB, thus allowing nuclear 
translocation of NF-κB. 
It is mechanistically proven that inflammation produces reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). In particular, ROS and RNS lead to oxidative damage and 
nitration of DNA bases, which increases the risk of DNA mutations and further leads to 
cancer. Nitric oxide (NO) is associated with inflammatory reaction and is produced by 
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inducible nitric oxide synthase (iNOS) in certain cells activated by various proinflammatory 
agents. NO acts as a host defense by damaging membranes of pathogenic bacteria and as a 
regulatory molecule with homeostatic activities. However, excessive production of NO is 
pathogenic for host tissue itself because NO, as a reactive radical directly damages functions 
of normal tissue. Thus, effective inhibition of NO accumulation by inflammatory stimuli 
represents a beneficial therapeutic strategy [38,39]. 
Nagaoka et al. [40] reported that CAPE possesses potent NO inhibitory activities and 
suggested that the NO inhibitory effect can directly correlate with anti-inflammatory 
properties of the Netherlands propolis. They suggested that the active principles of the 
Netherlands propolis, i.e., CAPE and its analogues, should block the activation of iNOS 
through the suppression of NF-kB activation and resulted in potent NO inhibition. 
We investigated the anti-inflammatory and antioxidant potential of CAPE on a tumor cell 
line (ZR-75-1). We found that CAPE at the concentration of 15μM inhibited NO production 
by (› 47%) compared to NO level of untreated tumor cells (P‹ 0.05). In addition, superoxide 
dismutase (SOD) was at the highest level in the maintained basal tumor culture cell 
supernatant ( 231.9± 4.2 μU/L). This level reduced intensively to (169.3 ± 3.7 μU/L), in the 
CAPE-treated culture cells, which was significantly less than the level in untreated cells ( 
P‹0.001). On the other hand, malonaldehyde (MDA) level, which is considered to be an 
important parameter for the oxidative damage determination, was inhibited to ( 17.3 ± 2.3 
μmol/L) in the CAPE-treated cells when compared with untreated tumor cells (23.8 ± 2.5 
μmol/L), but was not statistically significant (Table 1). 
 
MDA 
(μ mol/L) 
SOD 
( μ U/ L ) 
 
 
NO· 
(μ mol/L) 
 Group Parameters 
23.8 ± 2.5 231.9 ± 4.2  19.6 ± 1.9  I 
17.3 ± 2.3 169.3 ± 3.7  10.2 ± 1.3  II 
 
N.S ‹ 0.001  ‹ 0.05  P 
(I). Untreated tumor cells , (II). Treated tumor cells at 15μM CAPE. 
Table 1. Nitric oxide (NO·), Superoxide dismutase (SOD) and Malondialdehyde (MDA) values in 
culture supernatant. 
2.2. Regulation of tumor cell development by CAPE 
Under normal physiological conditions, the human body maintains homeostasis by 
eliminating unwanted, damaged, aged, and misplaced cells. Homeostasis is carried out in a 
genetically programmed manner by a process referred to as apoptosis (programmed cell 
death). Cancer cells are able to evade apoptosis and grow in a rapid and uncontrolled 
manner. One of the most important ways by which cancer cells have gained this ability is 
through mutation in the p53 tumor suppressor gene. Without a functional p53 gene, cells 
lack the DNA-damage-sensing capability that would normally induce the apoptotic cascade 
[41-43]. 
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A complex set of proteins, including caspases, proapoptotic and antiapoptotic B cell 
lymphoma (Bcl)-2 family proteins, cytochrome c, and apoptotic protease activating factor 
(Apaf)-1, execute apoptosis either by an intrinsic or extrinsic pathway. The intrinsic 
pathway is mitochondria dependent, whereas the extrinsic pathway is triggered by death 
receptors (DRs). Some antiapoptotic proteins such as Bcl-2 and B cell lymphoma extra large 
(Bcl-xL) and survivin are overexpressed in a wide variety of cancers. Therefore, selective 
downregulation of antiapoptotic proteins and upregulation of proapoptotic proteins and 
p53 in cancer cells offer promising therapeutic interventions for cancer treatment [44,45]. 
We tested the effect of CAPE on the viability of human breast cancer ZR-75-1 cells derived 
from a malignant ascitic effusion in a 63 year-old, white female with infiltrating ductal 
carcinoma [46]. CAPE induced a significant inhibitory effect on the growth and viability of 
tumor cells in vitro. We observed that this inhibitory action was highly dosage and time-
dependent. The maximum inhibitory action was obtained at 15μM (Figure 2A) on culture 
media. 
 
Figure 2. CAPE induced ZR-75-1 cell death (A); cell viability was observed in tumor cells treated with 
different CAPE concentrations (5, 10, 15 and 20μM), while (B) cells showed maximum alteration of 
viability at 48 hrs. of incubation, indicating that CAPE induced cell death in a dose and time dependent 
manner. The results shown in the histogram were the mean ± S.D. Assay was performed in 12 – well 
plate (2 x 106 ) cells/well, using trypan blue dye for viability detection. 
On the other hand, after 48 hours of administration, the percentage of cell death increased 
significantly to 49.6±6.9 (Figure 1B). No further changes were observed after 72 hours of 
treatment. To investigate the induced effect of apoptosis on cell viability, we analyzed the 
DNA fragmentation using DAPI. The nuclear structure exhibited condensation and 
fragmentation of some nuclei that were caused by 15μM CAPE at 48 hours. Apoptotic cells 
count significantly increased by 27% as compared to control tumor cells (P ‹ 0.01) (Figure 3B) 
[47]. 
Additionally, the microscopic examination did not reveal any signs of morphological 
changes after 12 hours of administration. However, a scattered retraction of the monolayer, 
vacuoles, and the granulation of the cytoplasm were observed after 24 hours. The 
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alterations were further aggravated after 48 hours. The cells were rounded up. Later, they 
became phase-dense and formed floating aggregates, which gradually increased in size and 
most of the cells were detached from the flasks. The cell membranes burst, which was 
followed by a gradual decrease of the cell count. These changes were not reversible. 
Transferring the cells into a fresh medium did not alter their state (Figure 4) [47]. 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of CAPE on expression of apoptotic cells. (A) ZR-75-1 cells without treatment. (B) Cells 
were treated with 15μM CAPE for the indicated time of 48 hrs. Condensation and apoptotic bodies 
were examined by immunofluorescence microscopy. Magnification, X20.  
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Figure 4. CAPE induced cell detaching (A) ZR-75-1 cells kept without treatment during experiments. 
(B) 15μM CAPE treatment after 48 hrs. Morphology changes in cells were examined by phase-contrast 
microscopy. Magnification, X40. 
2.3. Tumor growth inhibition in vivo by CAPE 
The effects of CAPE on the survival of mice bearing tumor are shown in figure 5. The 
median survival time for the untreated group of mice was 21 days. On the other hand, the 
group of mice bearing tumor and treated with 10mg/kg S.C/ every 5 days had a median 
survival time of 29 days. Two mice were completely cured. The median survival time of the 
group treated with 15mg/kg S.C/ every 5 days was found to be 43 days and 3 mice were 
completely cured. However, those mice treated with 5mg /kg S.C/ every 5 days did not 
show any remarkable changes in their survival percentage. It has also been observed that 
giving treatment more than once a week caused sores and increased irritability in the mice, 
vehicle (1:1/DMSO: NaCl). 
We studied the effect of CAPE (15mg/kg S.C/ every 5 days) on the growth of transplanted 
Ehrlich carcinoma into Swiss mice. The solid tumor volume showed a reduced rate in 
CAPE-treated mice and appreciably smaller volume (1.9 ± 0.46) mm³, with respect to the 
untreated group (3.7 ± 0.82) mm³. This value was significant (P‹ 0.01). The difference was 
observed from the beginning of tumor measurement i.e. since the 6th day after tumor 
implantation to the host, and was maintained until the end of observation (Figure 6). This 
finding is one of the characteristic effects of anti-tumor drugs. It is also in accordance with 
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the other findings, which suggest that subcutaneous administration of an aqueous crude 
water-soluble propolis (CWSP) resulted in marked regression of transplanted tumors [48]. 
 
 
Figure 5. Effect of CAPE treatment on the time of survival for mice bearing solid tumor at different 
doses compared with untreated group. 
 
Figure 6. Effect of CAPE (15mg/kg S.C), once/week and twice/week treatment on tumor volume against 
untreated group of mice. Data represented as mean ± S.D.  
The percentage of apoptotic cells with hypodiploid DNA content was determined from 
DNA histograms. Untreated tumor-bearing mice showed a peak pattern which represented 
proliferative and high metastatic tumor activity (Figure 7A). However the mice which had 
their tumor treated at 15mg/kg S.C did not alter the relative size of the peak, but induced a 
significant parallel shift to less-intense fluorescence (D- area). This decrease in the intensity 
and shift may be termed as nuclear apoptosis and fragmentation (Figure 7B). 
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Figure 7. The value in the tumor apoptosis histogram was higher in mice-bearing tumors, which were 
treated with CAPE (15mg/kg/S.C). (B) as compared to mice-bearing tumors untreated with CAPE (A). 
The apoptosis was identified by PI staining (D-area) with increased DNA fragmentation [47]. 
Chung et al., [49] showed that both CA and CAPE selectively inhibit matrix 
metalloproteinases (MMP) 2 and 9. CAPE inhibited strongly MMPs 2 and 9 with IC50 of 2–
5μM, while CA required 10–20 μM for such inhibition. In contrast, MMPs 1, 3, 7 and 
Cathepsin-K were not completely inhibited by either of them. CA and CAPE had a dose-
dependent inhibitory effect on the proliferation of HEPG2 cells. In HepG2 cells, CA at the 
concentration of 200 μg/mL reduced the viability to 61% , while CAPE, at 10 times lower 
concentration, inhibited the viability to 72% as compared to the respective controls. CAPE 
and CA suppressed the MMP 9 expression in HepG cells exposed to phorbol 12-myristate 
13-acetate (PMA). They also confirmed that CA (20 mg/kg) and CAPE (5mg/kg) repressed 
the growth of HepG2 tumor xenografts in nude mice as well as liver metastasis when 
administered subcutaneous or orally. Finally they concluded their observation that CA and 
its derivative CAPE: (1) inhibited the enzymatic activity of MMP-9 that plays an important 
role in cancer invasion and metastasis, (2) blocked the invasive potential through the 
suppression of MMP-9 gene transcription by inhibiting NF-κB function in PMA-stimulated 
HepG2 cells and (3) suppressed the growth of HepG2 cell xenografts in nude mice. 
Therefore, these two drugs were reported as strong candidates for treatment of cancer and 
metastasis via dual mechanisms (dual inhibition of metastasis-specific enzyme activity and 
gene transcription) [50]. 
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2.4. Regulation of tumor cell proliferation by CAPE 
Dysregulated proliferation is one of the major characteristics of tumorigenesis. In normal 
cells, proliferation is regulated by a delicate balance between growth signals and antigrowth 
signals. Cancer cells, however, acquire the ability to generate their own growth signals and 
become insensitive to antigrowth signals [51]. Their growth is controlled by cell cycle 
regulators at the G1/S-phase boundary, in the S phase, and during the G2/M phases of the 
cell cycle. A precise set of proteins called cyclins and cyclin-dependent kinases (CDKs) 
control the progression of cell cycle events. Whereas cyclin binding is required for CDK 
activity, CDK inhibitors (CKIs) such as p21 and p27 prevent CDK activity and prevent cell 
cycle progression. The G1-to-S-phase transition also requires cellular v-myc 
myelocytomatosis viral oncogene homolog (c-Myc), and inhibition of c-Myc expression 
leads to growth arrest [52,53]. 
The expression of c-Myc in turn is regulated by cdc25, a phosphatase that activates CDKs. 
The well-characterized tumor suppressor p53 has been implicated in controlling the G1-to- 
S-phase transition and in blocking cell cycle progression at the G1 phase in response to DNA 
damage [54]. A number of genes controlling cell cycle progression, including the CKI p21, 
are transcribed in a p53-dependent manner [55,56]. 
Rb is a tumor suppressor retinoblastoma protein that, like p53, functions as a negative 
regulator of cell growth [57]. Rb inactivation or deletion has been found in many cancers, 
including retinoblastomas and carcinomas of the lung, breast, bladder, and prostate. By 
binding to and inhibiting transcription factors such as elongation 2 factor (E2F), which are 
necessary for S-phase entry, Rb is believed to inhibit cell cycle progression [58]. On the other 
hand, phosphorylation of Rb (pRb) by CDK/cyclin complexes results in the release of active 
E2F species to stimulate the transcription of genes involved in DNA synthesis and S-phase 
progression [59,60].  
Currently, a number of inhibitors based on cell cycle regulators, including nutraceuticals, 
are being developed as therapeutic intervention for cancer prevention. Nutraceuticals have 
been shown to have potential in cancer prevention for halting cell cycle progression by 
targeting one or more steps in the cell cycle. Most nutraceuticals prevent the transition of 
cancer cells from the G1 to S phase. Some of these nutraceuticals act through p53 and some 
through Rb. Acetyl-keto-beta-boswellic acid was shown to arrest colon cancer cells at the G1 
phase, which was associated with decreases in cyclin-D1, cyclin-E, CDK-2, CDK-4, and pRb 
and an increase in p21[61]. 
In Ehrlich ascites tumor cells, acetoxychavicol acetate was shown to stimulate the 
accumulation of tumor cells in the G1 phase of the cell cycle, which was accompanied by a 
decrease in pRb and an increase in Rb [62]. β-Escin, a triterpene saponin, induced cell cycle 
arrest at the G1/S phase by inducing p21 and reducing pRb in a p53-independent manner in 
HT-29 human colon cancer cells [63]. In gastric cancer cells, curcumin was shown to 
suppress the transition of cells from the G1 to S phase, which was accompanied by a 
decrease in cyclin-D1 and p21-activated kinase 1 activity [64]. 
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The therapeutic goal of cancer treatment is to induce apoptotic death of cancer cells rather 
than necrosis due to the deleterious consequences of the latter, which include leakage of 
lysosomal enzymes to the extracellular media and spawning a substantial inflammatory 
reaction. Several investigators have demonstrated that CAPE has an anti-proliferative effect 
and an apoptosis inducing effect against various tumor cell lines. Cavaliere et al., showed 
that CAPE treatment increased the percentage of cells in G0/G1 and decreased the 
percentage of cells in S and G2/M phase in addition to its ability to inhibit DNA, RNA, and 
protein synthesis , thus delaying cell cycle progression to G2/M phase. CAPE also caused 
high levels of apoptotic cell death of 77.1%, with no signs of significant necrosis in PL104 
cells [65]. Also, Wang et al., demonstrated that CAPE treatment was associated with a strong 
inhibition of proliferation in a dose- and time-dependent manner, along with induction of 
G0/G1 arrest and apoptosis in HCT116 cells [66]. 
2.5. Regulation of tumor cell invasion by CAPE 
Tumor cell invasion and metastasis are interrelated processes involving cell growth, cell 
adhesion, cell migration, and proteolytic degradation of tissue barriers such as the 
extracellular matrix and basement membrane. Several proteolytic enzymes, including 
MMPs (chiefly MMP-2 and MMP-9) [67,68] and intercellular adhesion molecule (ICAM; 
chiefly ICAM-1), participate in the degradation of these barriers [69,70]. A number of studies 
in lung, colon, breast, and pancreatic carcinomas have demonstrated overexpression of 
MMPs in malignant tissues compared with adjacent normal tissues [71-78]. Apart from 
MMPs, cysteine proteases [79] and serine proteases [80] such as urokinase-type plasminogen 
activator (u-PA) have also been involved in the invasion and metastasis of cancer cells. Since 
both u-PA and u-PA receptor (u-PAR) contain binding sites for NF-κB and activator protein 
(AP)-1 in their promoter regions [81-83], inhibition of these transcription factors will 
eventually result in the inhibition of u-PA–u-PAR complex and subsequent suppression of 
invasive behavior. 
Furthermore, Hwang et al. [84] investigated the effect of CAPE on tumor invasion and 
metastasis in HT 1080 fibrosarcoma cells by determining the regulation of matrix 
metalloproteinases (MMPs). HT 1080 cells were treated with increasing concentration of 
CAPE and the m-RNA transcripts of MMP-2 and MMP-9 were analyzed using semi-
quantitative RT-PCR. Both MMP- 2 and 9 proteins levels were significantly suppressed in 
a dose dependent manner. Gelatin zymography also indicated constitutively expressed 
MMP-2 and 9 proteins in HT 1080 cells, which gradually reduced after treating with 
CAPE. To further corroborate the down regulation of MMP-2, activation studies of pro-
MMP2 were performed using organomercuric compound, 4-aminophenylmercuric acetate 
(APMA), and the result indicated the down regulation of MMP-2 by CAPE. It has been 
shown that mRNA levels of tissue inhibitor of matrix metalloproteinases (TIMPs) and 
membrane type-matrix metalloproteinases (MT-1 MMPs) were also reduced significantly. 
CAPE also inhibited the cell invasion, cell migration and colony formation of tumor cells. 
Thus CAPE acts as a vital antimetastatic agent, by inhibiting the metastatic and invasive 
potential of malignant cells. 
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2.6. Regulation of tumor cell angiogenesis by CAPE 
Angiogenesis, the process during which new blood vessels are formed from preexisting 
ones, can be classified as either physiological or pathological. Physiological angiogenesis 
provides a driving force for organ development in ontogeny, is necessary for ovulation, and is 
a prerequisite for wound healing; pathological angiogenesis occurs during tumor growth at 
primary and metastatic sites [85]. The angiogenic cascade during tumor development consists 
of the release of angiogenic factors, binding of angiogenic factors to receptors on endothelial 
cells (ECs), EC activation, degradation of the basement membrane by proteases, and migration 
and proliferation of ECs. Adhesion molecules then help to pull the sprouting blood vessels 
forward, and ECs are finally organized into a network of new blood vessels [86].  
The signaling pathway governing tumor angiogenesis is exceedingly complex, involving 
various angiogenic mediators. The major signaling mediators include VEGF, platelet-
derived growth factor, fibroblast growth factors (FGFs), epidermal growth factor, ephrins, 
angiopoietins, endothelins, integrins, cadherins, and notch [87]. 
 
P2  P1 Treated Group
n = 10 
Tumor Group
n = 10 
Normal Group
n = 10 
Group 
Parameters 
P‹ 0.01  P‹ 0.001 142.1 
 
84.5 – 196.3 
181.9 
 
88.2 – 216.1 
130.9 
 
79.6 – 166.4 
 
MMP-9 (ng/ml )
 
Median Range 
 
P‹ 0. 01 
 
P = 0.01 1.9 
 
 
1.3 – 9.3 
1.4 
 
 
1.0 – 5.4 
2.2 
 
 
1.1 – 6.3 
Endostatin 
(ng/ml) 
 
Median Range 
P1 Tumor group Vs Normal group 
P2 Treated group Vs Tumor group 
Table 2. Levels of MMP-9 and Endostatin serum in normal mice group, tumor bearing group and 
treated tumor group. 
We found that the untreated mice bearing Ehrlich tumor elicited a highly significant 
increase of serum MMP-9 level (181.9 ng/ml), which was reduced (142.1 ng/ml) in mice 
treated with CAPE at a dose of 15mg/kg (P‹ 0.01) close to the normal mice serum level. 
However, in the untreated mice bearing tumor serum endostatin (sE) was significantly 
lowered (1.4 ng/ml) compared with the normal mice. In CAPE-treated mice serum endostatin 
level was significantly higher (1.9 ng/ml) than the serum level in the untreated group (Table 
2)[47]. On the other hand, there was a negative correlation between (sMMP-9 and sE) and the 
total white blood cells (WBCs), hemoglobin (HB) and the platelet count of mice (Table 3)[47]. 
Based on these findings, we concluded that; the endogenous inhibitor of the angiogenic serum 
(endostatin) has been shown to be overexpressed, significantly higher in treated mice 
compared to untreated mice  (1.9 ng/ml), and nearly to the value of normal serum mice (Table 
2). These findings may help to utilize endostatin itself in the therapy. It also indicates that 
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CAPE has the potential of an anti-metastatic agent. It may mediate CAPE effects by inhibiting 
the cell proliferation. The findings of this study are in accordance with Schuch et al. [88] who, 
claimed that endostatin microbeads significantly inhibit the growth of subcutaneous 
choloromas in SCID mice as compared to control mice. On the other hand, MMP-9 and 
endostatin did not correlate with the white blood cells (WBCs), hemoglobin (HB) and platelet 
count (Table 3). It may be concluded that MMP-9 and endostatin are independent factors. 
 
  HB  WBCs Count 
 
 
 
Platelets Count 
MMP-9  R= 0.11, ›0.05  R= 0.19, ›0.05  R= 0.24, ›0.05 
Endostatin  R= 0.09, ›0.05  R= 0.1, ›0.05  R= 0.04, ›0.05 
Table 3. Correlation between investigated angiogenic factors and, hemoglobin (HB), white blood cells 
count (WBCs) and platelets count in tumor treated mice. 
3. Conclusion 
These findings obtained suggest that CAPE is a potent agent, which has antioxidant 
properties. In vitro findings support that CAPE could be potentially useful in the control of 
tumor cell proliferation as well as, an apoptotic-inducing agent. Furthermore, CAPE exhibits 
anti-metastatic and anti-angiogenic properties. CAPE could be potentially useful in the 
control of tumor growth in experimental models. Its action is accompanied by the shifting 
and elevating of the angiostatic and inhibiting angiogenic factors. Finally, it has been 
demonstrated that CAPE has many biological and pharmacological properties with 
predictive future applications in human clinical trials.  
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